These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33766261)

  • 1. Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease.
    Maas R; Rodionov RN
    J Am Coll Cardiol; 2021 Mar; 77(12):1551-1553. PubMed ID: 33766261
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease.
    Reddy R; Diaz P; Ramasamy R
    Eur Urol; 2022 Jan; 81(1):120-121. PubMed ID: 34772548
    [No Abstract]   [Full Text] [Related]  

  • 3. Phosphodiesterase-5 Inhibitors in Men With Stable Coronary Artery Disease.
    Wen Z; Feng Y; Jiang L
    J Am Coll Cardiol; 2021 Jul; 78(3):294-295. PubMed ID: 34266584
    [No Abstract]   [Full Text] [Related]  

  • 4. Erectile dysfunction in the cardiac patient.
    Kloner RA
    Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimization of the use of phosphodiesterase-5 inhibitors].
    Pushkar' DIu; Segal AS
    Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up.
    Raina R; Lakin MM; Agarwal A; Sharma R; Goyal KK; Montague DK; Klein E; Zippe CD
    Urology; 2003 Jul; 62(1):110-5. PubMed ID: 12837433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis of erectile dysfunction--what is still needed today?].
    Weiske WH
    Urologe A; 2003 Oct; 42(10):1317-21. PubMed ID: 14569379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
    Mason RG
    J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
    Kloner RA; Montorsi P; DeBusk RF
    J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835
    [No Abstract]   [Full Text] [Related]  

  • 10. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
    Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
    Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients.
    Carson CC
    Curr Urol Rep; 2003 Dec; 4(6):488-96. PubMed ID: 14622503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
    Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
    Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group.
    Giuliano F; Montorsi F; Mirone V; Rossi D; Sweeney M
    J Urol; 2000 Sep; 164(3 Pt 1):708-11. PubMed ID: 10953130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
    Gibson A
    Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
    Marchal-Escalona C; Herrera-Imbroda B; Clemente-Postigo M; Alcaide-Torres J; Quiñonero A; Marchal M; Queipo-Ortuño MI; Aragón IM; Martín-Morales A; Lara MF; Cardona F
    J Sex Med; 2016 Jul; 13(7):1104-10. PubMed ID: 27235284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
    Steers WD
    J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.